Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2011

Conditions
Cystic Fibrosis
Interventions
DRUG

Tobramycin

Trial Locations (1)

69500

RECRUITING

Centre de Ressource et de Compétence Mucoviscidose Pédiatrique Centre de Référence Mucoviscidose, Lyon

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Lyon

OTHER

collaborator

Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant (EPICIME)

UNKNOWN

collaborator

Clininfo S.A.

INDUSTRY

collaborator

Hospices Civils de Lyon

OTHER

lead

Erempharma

INDUSTRY